Výsledky vyhledávání - "Robert Toorawa"

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Autor: Bente Vangen, Eirik Søfteland, Juris J. Meier, Uli C. Broedl, Robert Toorawa, Mario Maldonado-Lutomirsky

Publikováno v: Diabetes Care. 40:201-209

OBJECTIVE To evaluate the efficacy and safety of empagliflozin versus placebo as add-on therapy in patients with type 2 diabetes and inadequate glycemic control with linagliptin and metformin. RESEARCH DESIGN AND METHODS Patients with HbA1c ≥8.0% a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de7bf8464f044aaf1590525071f8dce
https://doi.org/10.2337/dc16-1347

Zobrazit plný text záznamu

Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial

Autor: Maximiliano di Domenico, Michael A. Nauck, Sanjay Patel, Hans-Juergen Woerle, Maureen Kobe, Robert Toorawa

Publikováno v: Diabetesvascular disease research. 13(4)

Linagliptin plus pioglitazone single-pill combinations were evaluated. Patients ( n = 936) with insufficient glycaemic control, despite lifestyle interventions, were randomised for 30 weeks to either monotherapy with linagliptin 5 mg; pioglitazone 15

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32648331519d6f43567d85f74fc1271
https://pubmed.ncbi.nlm.nih.gov/27190087

Zobrazit plný text záznamu

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

Autor: Robert Toorawa, M. von Eynatten, Sandra Thiemann, Hans-Juergen Woerle, R. Harper, Sanjay Patel, Anthony H. Barnett

Publikováno v: Diabetes, Obesity and Metabolism. 14:1145-1154

AIMS To investigate the efficacy and safety of linagliptin, a dipeptidyl peptidase-4 inhibitor, in type 2 diabetes mellitus (T2DM) patients for whom metformin was inappropriate. METHODS This 1-year double-blind study (ClinicalTrials.gov, NCT00740051)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee32afa7748fe1433cebd9569de1329
https://doi.org/10.1111/dom.12011

Zobrazit plný text záznamu

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Autor: Elizabeth Rafeiro, Robert Toorawa, Hans-Juergen Woerle, Thomas Meinicke, Sonja Weber-Born, Stuart A. Ross

Publikováno v: Current Medical Research and Opinion. 28:1465-1474

Glycaemic control in patients with type 2 diabetes (T2DM) is often not achieved or not sustained using monotherapy such as metformin, necessitating the addition of other antihyperglycaemic agents. Linagliptin, a dipeptidyl peptidase-4 inhibitor, is l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6b7a2b13651f7dc32e6840eb083ed5b
https://doi.org/10.1185/03007995.2012.714360

Zobrazit plný text záznamu

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Autor: Robert Toorawa, Tony D’Urzo, Martina Gahlemann, Zuzana Blahova, Matjaž Fležar, Kai-Michael Beeh, Ekkehard Beck, Paul M. O'Byrne, Lorna Hart

Publikováno v: Respiratory Research

Background Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease. Methods Two multicentre studies examined the efficacy and safety of 4 weeks’

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df5bf3773d427de3061db7b7abe6853
https://doi.org/10.1186/s12931-015-0249-8

Zobrazit plný text záznamu

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Autor: Martina Gahlemann, Robert Toorawa, Kai-Michael Beeh, Craig LaForce, Arne Wenz, Matjaž Fležar

Publikováno v: Respiratory Research

Background A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks’ treatment with once-daily (QD) or twice-daily (BID) olodaterol (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49aaa53abf14a4951c966de81138981d
https://doi.org/10.1186/s12931-015-0243-1

Zobrazit plný text záznamu

Dose-Finding Study Of 4-Week, Once-Daily Treatment With Olodaterol, A Novel Long-Acting B2-Agonist, In Patients With Asthma

Autor: Martina Gahlemann, Ekkehard Beck, Kai-Michael Beeh, Zuzana Blahova, Robert Toorawa, Matjaz Flezar

Publikováno v: B33. ASTHMA THERAPY: NOVEL APPROACHES.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0081566d7ed1a0dced1b59d15dfd1fc
https://doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2764

Zobrazit plný text záznamu

Use of simulation to compare the performance of minimization with stratified blocked randomization

Autor: Robert Toorawa, Steve Jones, Mark Donovan, John Conlon, Michael Adena

Publikováno v: Pharmaceutical statistics. 8(4)

Minimization is an alternative method to stratified permuted block randomization, which may be more effective at balancing treatments when there are many strata. However, its use in the regulatory setting for industry trials remains controversial, pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ef48181f1edb0a31833e90b4d622da
https://pubmed.ncbi.nlm.nih.gov/18756580

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání